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Abstract
Breast cancer is the most common cancer among women. DESIREE is a European project which aims at developing
web-based services for the management of primary breast cancer by multidisciplinary breast units (BUs). We de-
scribe the guideline-based decision support system (GL-DSS) of the project. Various breast cancer clinical practice
guidelines (CPGs) have been selected to be concurrently applied to provide state-of-the-art patient-specific recom-
mendations. The aim is to reconciliate CPG recommendations with the objective of complementarity to enlarge the
number of patient situations covered by the GL-DSS. Input and output data exchange with the GL-DSS is performed
using FHIR. We used a knowledge model of the domain as an ontology on which relies the reasoning process performed
by rules that encode the selected CPGs. Semantic web tools were used, notably the Euler/EYE inference engine, to
implement the GL-DSS. We proposed to visualize the inferred recommendations as “Rainbow boxes”.
Introduction
Breast cancer is the most common cancer among women in France with about 50,000 new cases per year. After
having doubled between 1985 and 2005, the incidence rate of breast cancer seems now to be stabilized. However, if
it is decreasing for women aged 50-79 that benefit from the nationally organized screening, it has increased of more
than 60% for the women aged 30-39 and 40-491. With 12,000 deaths per year (figures consolidated in 2012), the
mortality rate of breast cancer in France is decreasing. Breast cancer is one of the cancers with the best survival rate
at five and 10 years (87%, resp. 76%). This may be explained by the evolution of therapeutics and the development
of endocrine and targeted agents as well as to the reduction of menopausal hormone therapy prescription. However,
breast cancer comprises a complex and heterogeneous group of diseases at the clinical, morphological, and molecular
levels. For some of the subtypes, especially the triple-negative and HER2+ breast cancers, margins for improvement
are both possible and necessary2.
Clinical practice guidelines (CPGs) are elaborated to provide best evidence-based recommendations for the manage-
ment of patients with specific conditions. Studies showed that implementing oncology CPGs does improve clinical
outcomes in both overall and recurrence-free survivals3. This is especially true in the case of breast cancer4. However,
despite the publication of CPGs and the provision of state-of-the-art recommendations, cancer management remains
subject to variable practices and poor levels of compliance with oncology CPGs are observed5, 6. For instance, Wo¨ckel
et al. reported a 51.9% guideline adherence rate for the complete treatment received by primary breast cancer patients6.
In the last decade, organisational measures such as multidisciplinary tumor boards (MTBs) have been introduced to
promote quality in care delivery to cancer patients7. The aim is to gather the various cancer specialists (surgeons, med-
ical oncologists, radiologists, pathologists, radiotherapists, etc.) to promote the collective discussion of cancer patient
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clinical cases and the decision of the best care plan for the patients. MTBs are expected to improve CPG implementa-
tion and to help capture cases for clinical trials. If studies on cancer care generally associate multidisciplinary tumor
boards with improvements of guideline compliance rates8–10, daily practice in MTBs is hampered by the complexity
of the disease and the vast amount of patient and disease data available. Implementing CPGs is difficult since a high
case load is actually discussed in MTBs and individual cases usually only receive a very limited amount of time for
review. Thus, the impact of multidisciplinary tumor boards has been questioned11, suggesting that decision support
tools could improve MTB efficiency.
Indeed, CPGs are usually developed by health professional societies and national health agencies as textual documents
in a narrative format. The sole dissemination of narrative guidelines poorly helps CPG implementation and has almost
no impact on physician decisions12. On the contrary, embedding CPGs in clinical decision support systems (CDSSs)
has shown some benefit on the improvement of physician decision compliance with CPGs13, 14. Different prototypes of
CDSSs supporting the management of breast cancer patients have been developed. However to the authors’ knowledge,
only few systems have been routinely used to support decisions made for actual breast cancer patients in real life breast
MTBs or breast units (BUs) and only some of them evidenced they were improving compliance of BU decisions with
CPGs. Among them, we can mention MATE15 which uses the PROforma language, OncoCure16 based on Asbru-
encoded protocols of pharmacological therapies for breast cancer, and OncoDoc17, 18 that offers to navigate through
a knowledge base structured as a decision tree to get patient-specific recommendations. Different formalisms have
been proposed to translate the narrative recommendations into computer-interpretable guidelines19. More recently,
research works using web semantic approaches have been conducted, e.g. Abidi et al. proposed to use ontologies in a
rule-based reasoning process to manage breast cancer patients20.
However, all previous propositions only rely on the modeling and implementation of a single CPG applied to a unique
pathology, in this case breast cancer. Other research works have developed solutions to handle the concurrent appli-
cation of different CPGs in order to manage patients with comorbidity that need different treatment regimens. Wilk
et al.21 have proposed a framework based on first order logic to represent CPGs and to mitigate possible adverse in-
teractions (drug-drug or drug-disease) between the recommendations provided by the different CPGs. Galopin et al.22
have implemented an ontological reasoning process to allow for the flexibility necessary to deal with patients suffering
from both hypertension and type 2 diabetes. In these cases, CPGs are reconciliate on the basis of competition.
DESIREE is a European-funded project† which aims at developing a web-based software ecosystem for the person-
alized, collaborative, and multidisciplinary management of primary breast cancer by BUs. DESIREE would offer
guideline-based, case-based, and experience-based23 decision support. The system is expected to be used by the
clinical partners of the consortium on actual breast cancer patients in real life BUs. In this perspective, we have
translated the different contemporary breast cancer CPGs that clinical partners are implementing in their BUs in a
computer-interpretable format. The aim is to reconciliate breast cancer CPGs on the basis of complementarity and to
concurrently apply all of them. The idea is to avoid the CDSS silence observed when single CPGs are implemented
and no recommendation is issued for a clinical case not covered by these CPGs, and to provide the recommendations
inferred by the other breast cancer CPGs.
In this paper, we present the guideline-based decision support system (GL-DSS) of DESIREE and describe how we
used a domain ontology as the conceptual and terminological structure on which relies the reasoning process performed
from the rules that model the selected breast cancer CPGs. We also propose an original visualization of the output of
the concurrent application of CPGs as “rainbow boxes”24.
Material and methods
General design of the GL-DSS and basic workflow
The aim of the GL-DSS of DESIREE is to provide state-of-the-art guideline-based recommendations structured as
action plans issued from multiple breast cancer CPGs for any clinical case discussed by BUs. Informed BU participants
may then choose to comply of not with one of the options provided. Since patient clinical cases discussed during BUs
may be more or less complete, and because clinical data and reasoning process may be described at various levels
†http://www.desiree-project.eu
of abstraction, we chose to use semantic web tools allowing for subsumption. A data model and a knowledge model
dedicated to breast cancer management were consistently developped. The data model relies on a standard entity-
relationship model.The Breast Cancer Knowledge Model (BCKM) is a specification of all concepts that have been
identified for the management of breast cancer patients, structured as an OWL ontology. It enables the multi-level
description of patient cases and of recommended action plans. The BCKM is a central static resource shared by all
data-oriented modules and components of DESIREE, so that they can be semantically interoperable.
To elaborate the knowledge base of the GL-DSS, the first step of the method was to select the different breast cancer
CPGs to be used. Once validated by the clinical partners of the DESIREE consortium, each of the considered CPGs
has been first structured as a set of human-readable decision rules, then encoded into a formal model-driven rule
language (NRL). Each formalized CPG was then processed in order to check its consistency regarding the BCKM and
to generate an internal computer-interpretable representation of the rules in the N325 notation‡.
In the DESIREE project, a patient data repository, part of the DESIREE Information Management System (DESIM),
constitutes a local breast-cancer-specific Electronic Medical Record (EMR) to store all patient cases according to the
common data model. In order to be interoperable beyond the DESIREE system, we decided to align both the knowl-
edge and the data models with standard reference terminologies to address semantic interoperability, and we chose the
FHIR messaging standard for communicating with external components to warranty syntactic interoperability26.
Finally, we expected the GL-DSS to be used in real life BUs for actual patients. Thus, we needed to demonstrate good
performance of the system. That is why we chose to use a fast and powerful rule based inference engine (Euler/EYE27).
The GL-DSS module is implemented as a servlet providing web services through the use of a REST API. Figure 1
illustrates the different internal components of the GL-DSS, the external ressources, and data flows. At runtime, the
GL-DSS queries a FHIR server, linked to DESIM, for patient data. Then, it converts the received bundle of FHIR
resources into an internal N3 representation . On the basis of N3 rules and of the N3 version of the BCKM, the
inference engine produces new facts, including the set of recommended action plans, which are returned to the user.
Clinical practice guideline collection and structuration
Various CPGs have been published for the management of breast cancer both at the international and national levels.
Our goal was to identify up-to-date CPGs that would be implemented within the GL-DSS module of DESIREE. The
selection criteria were: primary breast cancer; no restriction on the management step (including diagnosis, therapy,
and follow-up); published in English, or in the languages of the project’s clinical partners (Spanish and French); most
recent version when several versions existed. We conducted a search through different online resources: (i) biomedical
literature, using PubMed, (ii) international and national web repositories of CPGs including governmental healthcare
agencies (e.g. NGC, G-I-N, NCI...)§, (iii) websites of professional societies and associations, healthcare institutions
(e.g. NCCN, ESMO, ASCO, SEOM...), and (iv) custom local CPGs used as references by clinical partners’ BUs.
Eight CPGs were finally validated by the clinical partners of DESIREE and chosen for implementation within the
project: two NCCN guidelines Version 2.2016 ”Breast Cancer” and ”Genetic/Familial High-Risk Assessment: Breast
and Ovarian” [English]; the ESMO guidelines published in Annals of Oncology published in 2015 [English]; the
SEOM clinical guidelines for early-stage breast cancer published in 2015 [English]; three CPGs from the Paris public
hospitals (AP-HP), guidelines for “breast cancer management” (2016), for “fertility preservation” (2016), and for the
“management of cancer and pregnancy” (2014) [French]; the Onkologikoa’s breast cancer guidelines 2016 [Spanish].
Each CPGs has been structured by a medical oncologist specialized in the management of breast cancer as human-
readable IF-THEN decision rules. The rules built have been double-checked by a public health physician. Then, they
have been normalized to comply with the domain concepts defined by the breast cancer knowledge model.
‡N3 is a compact and human readable syntax for RDF serialization but it has several features that go beyond a serialization for RDF models,
such as support for RDF-based rules. It has currently the status of a W3C submission whose specifications dated back to 2011 can be found at
http://www.w3.org/TeamSubmission/2011/SUBM-n3-20110328/
§NGC = The National Guideline Clearinghouse (http://www.guideline.gov), G-I-N = Guideline International Network (http://www.g-i-n.net),
NCI = National Cancer Institute (http://www.cancer.gov), NCCN = National Comprehensive Cancer Network (http://www.nccn.org), ESMO =
European Society for Medical Oncology (http://www.esmo.org), ASCO = American Society of Clinical Oncology (http://www.asco.org), SEOM =
Spanish Society of Medical Oncology (http://www.seom.org).
Figure 1: Guideline Based Decision Support System - General design and workflow.
The Breast Cancer Knowledge Model
The purpose of the knowledge model is to provide a common reference and terminology for all modules and com-
ponents with the guaranty that clear, unique, and accredited concepts and definitions are being used. All the relevant
concepts used for a patient case description and for the reasoning process are stored in a single place as an ontology in
the OWL format. The choice to define a specific terminology focusing on the breast cancer domain was mainly made
in order to be able to easily add new concepts. Nevertheless, the model remains tightly coupled with some existing
established authoritative terminologies such as the NCI thesaurus, LOINC, and SNOMED CT, to further warranty se-
mantic interoperability with potential health information systems (HISs) or EMRs. Alignment is maintained through
links whenever it is possible by means of systematic annotations (See figure 2). All the relevant clinical procedures,
possible examinations, clinical findings, and observations are present in the model.
The ontology also accounts for the breast cancer data model which includes the main concepts such as Patient, Side,
and Lesion which are the main entities characterized by series of parameters or attributes, and allow for the description
of a breast cancer patient case. Consequently, from the decision support point of view, the BCKM ontology is divided
into two main hierarchies. The first one contains all the concepts specific to the DESIREE environment, namely the
concepts used to define the entity parameters, and the second one contains all reference concepts defined in the breast
cancer domain. The reference concepts are maily used as potential values for the former DESIREE concepts.
Figure 2: Example of a reference concept and its link with standard terminologies.
Decision rules formats
We followed the approach promoted by the HL7 CDS group on the notion of “knowledge artifact”28 to represent
rule sets. Rules are first encoded in a formal language, human readable, and possibly writable by some trained
clinicians. We used NRL29 which is a model-driven language allowing to write logical expressions matching model
components and rules, independently of any implemented inference engine. In our approach, the BCKM ontology
acts as the reference model; an XSD model is automatically derived from the OWL model to feed the NRL parser
that validates rule specifications. NRL has already been used to manipulate clinical information models30 and is
similar to the GELLO language. NRL rule sets are then transformed into an XML representation, depending on the
model, but independent from the source format (NRL) and the target computer-interpretable format. This intermediate
representation is close to the HL7 Clinical Decision Support Knowledge Artifact Specification28 and is used to be
shared by other modules (e.g., the experience-based DSS23). Another transformation yields an N3 representation25 of
the NRL rules which is the target computer-interpretable format.
Data representations
Patient-related data is stored outside the GL-DSS, within the DESIM component. Input and output data exchange with
the GL-DSS is performed using FHIR. No specific FHIR profile was defined and only standard FHIR resources were
used, mainly Patient, Observation, Condition, BodySite and Specimen. In order to preserve the data model through the
FHIR transport, the main assumption has been that the observation resource was used to convey parameter-value pairs
of the model. DESIREE codes defined in the DESIREE namespace of the knowledge model are used to particularize
these observations and make them describe the same concepts as those used by the GL-DSS. Once parsed and decoded
from the FHIR messages, patient data are converted to N3 notation25 and the data model is instanciated as a set of
triples. This N3 representation is matched with the N3 excecutable rules by the inference engine at runtime.
Execution engine
To combine rule-based reasoning and ontological reasoning, we adopted Euler, more specifically the EYE implementa-
tion by De Roo et al. This provides the system with description logic (DL) reasoning facility along with some classical
logic powerful features31. Euler is notably using Notation3 (N3), it is directly interoperable with the knowledge model
since it belongs to the same family of semantic web tools able to deal with graphs of triples. Moreover, it appeared to
be among the fastest reasoners with a full OWL-DL27, 32.
In the GL-DSS module, the engine is fed with a set of N3 rules and a set of N3 facts produced from the patient data
according to the knowledge model concepts and properties. It takes the full knowledge model as additional input and
using a generic query it then saturates the knowledge base until no more new triple can be produced generating new
inferred facts. The content of the triple store is then explored in order to build new recommendations that have been
produced with the basic concepts and building primitives from the knowledge model.
Visualization of recommendations
In order to display the multiple recommendations that may be produced by the different CPGs, we adapted the rainbow
boxes visualization technique designed by Lamy et al.24 for the comparison of drug properties. It performs overlap-
ping set visualization, a visualization problem that considers elements and the sets made out of these elements. The
objective of the visualization is to clearly display which elements a given set includes, and which sets a given element
belongs to, to facilitate the discovery of new knowledge such as similarities between elements or sets.
Rainbow boxes represents the elements in columns and each set is displayed as a rectangular labeled box that covers
the columns associated with the elements belonging to the set. The boxes are stacked vertically as pieces in a Tetris
game, and ordered by size (largest ones at the bottom). “Holes” can occur in a box, when the elements belonging to a
given set are not in consecutive columns. However, the column are ordered using a heuristic algorithm that minimize
the number of holes.
The presentation of multiple recommendations can be seen as an overlapping set visualization problem where each
recommendation is a set of therapeutic units. Thus, in this context, a set is a recommendation and an element is a
therapeutic unit. Therapies are grouped in six categories (pre-operative chemotherapy, pre-operative endocrine therapy,
surgery, post-operative chemotherapy, radiotherapy, post-operative endocrine therapy) displayed from left to right,
and each of the four types of therapies (surgery, chemotherapy, radiotherapy, endocrine therapy) were distinguished
by color hues. In addition, some recommendations have a temporal dimension, e.g. chemotherapy with Adriamycin-
Cyclophosphamide followed by Docetaxel. Color saturation is used to emphasize the first step of the recommendation.
A case study
As an illustration of how the GL-DSS operates, we present a case study processed with two of the breast cancer
management CPGs that were selected in the DESIREE project, namely the 2016 version of NCCN CPGs “Breast
cancer” and the 2016 version of AP-HP CPGs “Breast cancer management”. Both guidelines have been formalized as
human readable IF-THEN rules by an oncologist specialized in breast cancer.
We consider the case of a patient, aged 67, diagnosed with an invasive bifocal breast cancer of the lower outer quad-
rant of the left breast. The first lesion is 35 mm, and the second 12 mm and the distance between the two is 18 mm.
There is no clinical axillary lymph node (cN0). The two lesions have the same pathologic profile: Estrogen receptors
(ER)=95%, Progesterone receptors (PR)=40%, HER2-, SBR 3, and KI67=25%. The patient has no contra-indication
to chemotherapy. Patient data is transmitted using a FHIR message to the GL-DSS and translated into the N3 format.
Some preliminary inference rules are triggered to enrich the patient profile and assess the postmenopausal status, the
TNM staging as T3 N0 M0, the stage as IIa, and the positive hormonal receptor status (HR). Figure 3 displays an
excerpt of NCCN and AP-HP rules triggered on this patient case. NCCN guidelines recommend two management
strategies either surgery (lumpectomy and sentinel node excision or mastectomy and sentinel node excision) or sys-
temic therapy: endocrine therapy with aromatase inhibitors or chemotherapy with the proposition of two different
protocols (AC followed by Paclitaxel and TC). In the same way, AP-HP guidelines propose both surgery and systemic
therapy (see figure 4). However, both surgeries and systemic therapies are different: AP-HP CPGs recommend a
surgery by mastectomy with axillary dissection, there is no recommendation of endocrine therapy, and if some of the
chemotherapies are those recomended by NCCN CPGs, there are two additional protocols.
The rainbow boxes visualization of the case study is displayed in figuree 5. The box label indicates the guideline(s)
leading to the recommendation. When both CPGs produce the same recommendation, there are two labels, and thus
the box is larger. Consequently, it is easy to determine at a glance the most consensual recommendations. Similarly,
the use of color makes it easy to see that most recommendations involve chemotherapy. It is also noticeable that all
these chemotherapies include cyclophosphamide.
NCCN		
IF	Stage	=	Stage	I	OR	IIa	OR	IIb	OR	IIIa	
THEN	Lumpectomy	AND	Surgical	axillary	staging		
	
IF	Stage	=	Stage	I	OR	IIa	OR	IIb	OR	IIIa	
THEN	Mastectomy	AND	Surgical	axillary	staging	+/-	ReconstrucEon	
	
IF	Invasive	breast	cancer	AND	T	=	T2-T3	
THEN	PreoperaEve	systemic	therapy	
	
IF	(Stage	=	Stage	I	OR	IIa	OR	IIb	OR	IIIa)	AND	cN0	
THEN	Surgical	axillary	staging	=	SenEnel	node	excision	
	
IF	PreoperaEve	systemic	therapy	AND	HER2-	
THEN	Chemotherapy	
	
IF	PreoperaEve	systemic	therapy	AND	HR+	
THEN	Endocrine	therapy	
	
IF	Chemotherapy		
THEN	AC	(Doxorubicine-Cyclophosphamide)/Paclitaxel	
	
IF	Chemotherapy		
THEN	TC	(Docetaxel-Cyclophosphamide)	
	
IF	Endocrine	therapy	AND	Postmenopausal	status	
THEN	Aromatase	inhibitors	
	
AP-HP	
IF	Invasive	breast	cancer	
THEN	Breast	surgery	AND	Surgical	axillary	staging	
	
IF	MulEcentric	tumor	OR	Radiotherapy	contra-indicated	OR	T4-inﬂammatory	cancer		
THEN	Lumpectomy	contra-indicated	
	
IF	Breast	surgery	AND	Lumpectomy	contra-indicated	
THEN		Mastectomy	
	
IF	MulEcentric	tumor	AND	High	inter-lesion	distance		
THEN	Surgical	axillary	staging	=	Axillary	dissecEon	
	
IF	T	=	T2-T3	AND	N	=	N0-N1	
THEN	PreoperaEve	systemic	therapy	
	
IF	ER++	AND	PR=+/-	AND	SBR	=	2-3	AND	KI67	>	20%	
THEN	Luminal	B	
	
IF	PreoperaEve	systemic	therapy	AND	Luminal	B	
THEN	Chemotherapy	
	
If	Chemotherapy		
THEN	AC	(Doxorubicine-Cyclophosphamide)/Docetaxel		
	
If	Chemotherapy		
THEN	AC	(Doxorubicine-Cyclophosphamide)/Paclitaxel	
	
If	Chemotherapy		
THEN	TC	(Docetaxel-Cyclophosphamide)	
	
If	Chemotherapy		
THEN	DAC	(Docetaxel-Doxorubicine-Cyclophosphamide)	
	
IF	PreoperaEve	systemic	therapy	AND	Luminal	B	AND	Chemotherapy	contra-indicated		
THEN	Endocrine	therapy	
	
F	Endocrine	therapy	AND	Postmenopausal	status	
THEN	Aromatase	inhibitors	
	
Figure 3: Excerpt of NCCN and AP-HP rules triggered by the patient data.
Discussion
We have developed the GL-DSS module of the DESIREE project applied to the management of breast cancer patients.
The aim was to process the reconciliation of contemporary CPGs developed on a given pathology on the basis of com-
plementarity to extend the coverage of patient profiles for which the GL-DSS provides recommendations. Although
BU clinicians would have the opportunity to tick the CPGs they want to select to feed the GL-DSS, they may chose to
work with all of them to reduce the silence of the system or see when different CPGs are consistent.
The choice of developing the knowledge model as an ontology presents two major advantages on top of providing a
unique vocabulary to all the DESIREE project components: on the one side, the model resolves multilingual issues
through label language tags, which is strongly required in an international project and, on the second side, the inference
engine benefits from the ontological reasoning capabilities of the ontological model in addition to those provided by
the rule engine. For instance, the use of the subsumption relationship leads in some cases to decrease the number of
rules that have to be written and permits to match parameter values expressed at various levels of abstraction. In the
same way, the issued recommendations may have different levels of specialization depending on the granularity of the
information contained in the CPGs for a particular patient case.
Different approaches have been developed to represent and execute CPGs19. However, in the case of breast cancer
management, the choice of IF-THEN rules is appropriate to represent CPG contents since patient clinical data are
easily formalized and recommended actions are given as care plan described at a high level of abstraction, to be
implemented by care providers outside the BU. In the same way, the temporal nature of CPG recommendations is
Clinical	case		
Stage	IIA,	T2,	cN0,	mul6centric,	
35-12mm,	Δ=18mm,	OR=95%,	
PR=40%,	HER2-,	SBR3,	KI67=25%		
Lumpectomy	+	surgical	
axillary	staging	
Mastectomy	+	surgical	
axillary	staging	
Stage	IIa	
Stage	IIa	
T2	 Preopera6ve	systemic	
therapy	
Lumpectomy	+	sen6nel	
node	excision		
Mastectomy	+	sen6nel	
node	excision		
cN0	
cN0	
Chemotherapy	
Endocrine	
therapy	
HER2-	
AC	+	Paclitaxel	
TC	RH+	
Aromatase	inhibitors	
Clinical	case		
Stage	IIA,	T2,	cN0,	2	lesions,	
35-12mm,	Δ=18mm,	OR=95%,	
PR=40%,	HER2-,	SBR3,	KI67=25%		
Breast	surgery	+	surgical	
axillary	staging	Invasive	breast	
cancer	
T2,	N0	 Preopera6ve	systemic	
therapy	
Mastectomy	+	axillary	
dissec6on	
Mul6centric	
Endocrine	
therapy	
Luminal	B	
AC	+	Paclitaxel	
AC	+	Docetaxel	
Chemotherapy	contra-
indicated	
Aromatase	inhibitors	
Chemotherapy	
TC	
DAC	
NCCN	
APHP	
Figure 4: Recommendations inferred by NCCN and AP-HP guidelines on the patient clinical case.
easily represented by the ordered sequence of the therapeutic steps that compose the recommended care plan. We
could have chosen the HL7 Clinical Decision Support Knowledge Artifact Specification to define Condition-Action
rules but we considered the standard was not stable enough to be used in an international project stressed on the
production of outputs and outcome measures. In addition, a end-user formal language would still have been required,
and we preferred to use the NRL language which accepts any declared information model like our BCKM, instead of
using existing dedicated formalisms (like GELLO or Arden Syntax). IF-THEN rules have been manually built which
sets the issue of the scalability of the approach. If natural language processing (NLP) methods to semi-automatically
extract IF and THEN parts of rules have been proposed33, the result is not yet satisfactory and solutions for the
development of structured CPG contents should rely on the initial production of CPGs in these formats.
As for the execution engine, using tools from the semantic web domain as a base should have led to some kind of
solution based on SWRL rules associated to a classical OWL reasoning engine to produce inferences. However,
because of the lack of expressiveness of the latter, the impossibility to deal with non monotonicity and negation within
the open world assumption and the degraded performances obtained on a real scale with these techniques, we preferred
to adopt an alternative solution with Euler/Eye which does not have these limitations. When running the GL-DSS, the
different CPGs are operated, which may lead to intra and inter-CPG conflicting recommendations. Only intra-CPG
conflicts are resolved in the way proposed by34. The resolution of inter-CPG conflicts are left to the BU participants.
Currently, only two CPGs have been implemented, and work is still in progress with the other CPGs. It’s only when
all CPG rule bases would be developed that we will be able to assess the performance of the semantic reasoner
Euler/EYE and validate the choices we made. In addition, further evaluation in needed to assess the use of rainbow
Figure 5: Rainbow boxes visualizing the eight recommendations obtained for the case study. Therapies are presented
in columns, and there is one recommendation per rectangular box (not one per line). One box includes a hole in
the docetaxel column. Colors identify the four categories of therapies (green, yellow, red, in this case), the temporal
dimension (the vivid part of a box corresponds to the first step, while the dimmed part corresponds to the other steps
if any), and the guidelines (black and white labels).
boxes to visualize the set of concurrent recommendations provided by the different CPGs.
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